Spondyloarthritis & psoriatic arthritis
Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence
Authors' conclusion
SEC uptitration to 300 mg was associated with sustained improvements in disease activity and favorable retention and safety in axSpA patients with active disease after receiving SEC 150 mg
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) on SEC 150 mg for ≥ 3 months with active disease (ASDAS ≥ 2.1) at dose escalation; followed up to 24 months
- Participants
- 106 patients
- Exposure
- SEC uptitration to 300 mg after active disease on SEC 150 mg
- r-axSpAn = 77
- nr-axSpAn = 29
- Outcome
- Change in ASDAS over time
- Follow-up
- Up to 24 months
Methodological detailsmulticentre, real-world
- Multicentre
- Real-world
Main finding
As reported in the abstract
Median ASDAS, before vs after escalation
- Median ASDAS decreased from 4.1 to 2.0 in r-axSpA
- Median ASDAS decreased from 4.1 to 2.0 in nr-axSpA
- ASDAS significantly declined within 6 months and was sustained through 24 months
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Retention of SEC 300 mg · 6 and 24 monthsNo significant difference between subtypes | log-rank P = 0.48 |
- Retention of SEC 300 mg — Retention at 6 months
- 87.8%
- Retention of SEC 300 mg — Retention at 24 months
- 59.1%
ASDAS ≤ 2.1 at least once after escalation (overall)
- Patients achieving ASDAS ≤ 2.1
- 85.9%
HLA-B27 positivity and discontinuation risk
- Nonsignificant trend toward higher discontinuation risk
Safety
Adverse events
- AE incidence per 100 patient-years
- 15.79
- Mostly mild infections and cutaneous reactions; no new safety signals
Original publication
Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence. J Rheumatol. Published 15 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →